| Study design | Population | Size | Antibiotics | Control | Intervention | Analysis | Key findings |
---|---|---|---|---|---|---|---|---|
[26] | RCT | Acute salpingitis or PID | 40 | Co-amoxiclav 1 g three times daily doxycycline 200 mg once daily intravenously for 5 days followed by co-amoxiclav 500 mg three times daily for 15 days and doxycycline 200 mg once daily for 21 days | No NSAID | Piroxicam 20 mg/day from day 3 post-operation for 25 days | Per protocol | Tubal patency: in severe PID, bilateral patency was seen in 1/7 (14.2%) of placebo group versus 7/9 (77.8%) of intervention group (P = 0.02, Fisher’s exact test) |
Confirmed by laparoscopy | Residual adhesions: in severe PID, more patients in intervention group had no residual adhesions, 6/9 (66.7%), versus control group, 1/7 (14.3%) (P = 0.06, Fisher’s exact test) | |||||||
No difference between arms in tubal patency or residual adhesions for mild or moderate PID | ||||||||
[27] | RCT | Mild acute PID | 42 | Tetracycline 500 mg four times daily for 10 days | Placebo | Fentiazac 200 mg twice daily for 7 days | Intention to treat | Suprapubic pain: resolution of pain occurred by day 7 in 9/21 (43%) of patients in the intervention group versus 5/21 (24%) in the control group (P = 0.2, χ square) |
Clinical diagnosis | ||||||||
Reduction in overall signs and symptoms: greater reduction in average score for severity of signs and symptoms in the intervention compared with the placebo group (figures providing the basis of the calculation not provided) | ||||||||
Nausea reported in 4/21 patients receiving fentiazac (1 discontinuation) versus 2/21 in the control group (no discontinuations) |